PART I Item 1. B usiness. Overview We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers ("TCEs") for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties. They are naturally occurring immune cells that can intrinsically regulate immune responses and have the ability to differenti...
Q2 FY2026 — expected 2026-08-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-104181 | EDGAR | 99K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038738 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031486 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0000950170-23-010997 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0000950170-22-004101 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269447 | EDGAR | 63K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105028 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000950170-25-065609 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125537 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093943 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056910 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062018 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041482 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0000950170-23-021507 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024178 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0000950170-22-017132 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009658 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001193125-26-104144 | EDGAR | 3K words |
| 2026-02-27 | 0001193125-26-082539 | EDGAR | — |
| 2026-02-09 | 0001193125-26-041975 | EDGAR | — |
| 2025-12-19 | 0001193125-25-327097 | EDGAR | — |
| 2025-11-24 | 0001193125-25-292057 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269442 | EDGAR | — |
| 2025-10-27 | 0001193125-25-250756 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104986 | EDGAR | — |
| 2025-06-30 | 0001193125-25-152037 | EDGAR | — |
| 2025-06-04 | 0001193125-25-134487 | EDGAR | — |
117 total filings indexed. 90 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001740279 |
| Ticker | INAB |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.in8bio.com |
| Listed | 2021-07-30 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report